酪氨酸激酶抑制剂帕唑帕尼的药理与临床研究

Progress in pharmacological and clinical studies of the tyrosine kinase inhibitor pazopanib

帕唑帕尼为一种新型多靶点酪氨酸激酶抑制剂,临床用于治疗肾细胞癌。该药在临床前和临床研究中表现出了较强的抗肿瘤活性,且耐受性较好。文中通过文献检索对该药的药理作用、药动学、临床研究及安全性等进行了综述。

Pazopanib is a novel multi-targeted receptor tyrosine kinase inhibitor.It was proved to be used in the treatment of renal cell carcinoma.The preclinical and clinical researches have demonstrated that pazopanib has potent antitumor effects and is well tolerated.The mechanism of action,pharmacokinetics,clinical studies,and safety were reviewed in this paper.